CDTX News and Press, Cidara Therapeutics Inc. From 11/16/20

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been named a Top ...

Gainers: EuroDry (EDRY) +64%.Innodata (INOD) +32%.Akers Biosciences (AKER) +30%.XPeng (XPEV) +29%.Cidara Therapeutics (CDTX) +27%.Fossil Group (FOSL) +26%.Li Auto (LI) +23%.Sino-Global Shipping America (SINO) +22%.Celsius Holdings (CELH) +21%.Five Prime Therapeutics (FPRX) +16%...

Are These Good Penny Stocks To Buy Right Now? Looking for good penny stocks to buy right now? You and thousands of other traders are in the same position. Before you dive right into hitting the buy button, I think it’s important to understand what you’re buying, exactl...

Gainers: Akers Biosciences (AKER) +45%, Cidara Therapeutics (CDTX) +29%, Five Prime Therapeutics (FPRX) +24%, Zhongchao (ZCMD) +22%, Vaxart (VXRT) +22%.Losers: Applied Therapeutics (APLT) -12%, Soliton (SOLY) -13%, Harmony ...

Cidara Therapeutics (CDTX): Q3 GAAP EPS of -$0.41 misses by $0.01.Revenue of $2.42M (-87.3% Y/Y) misses by $1.49M.Press Release For further details see: Cidara Therapeutics EPS misses by $0.01, misses on revenue

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the thre...

Cidara Therapeutics ([[CDTX]] +1.0%) has announced new data from Phase 2 STRIVE trial of rezafungin, echinocandin for treatment and prevention of fungal infections, and CD377 preclinical data for influenza protection. Data were presented at IDWeek 2020.New analyses from completed Phase 2...

Presentations highlight clinical and preclinical progress of long-acting drug candidates for serious fungal and viral infections Posters presenting new a nalyses from completed Phase 2 STRIVE trial support the efficacy and ...

SAN DIEGO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two post...

SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two ora...